{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T12:49:33Z","timestamp":1750855773377,"version":"3.37.3"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K16288"],"award-info":[{"award-number":["23K16288"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jiac.2024.09.020","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T17:16:22Z","timestamp":1727370982000},"page":"102531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of baricitinib and corticosteroid compared to that of corticosteroid monotherapy in severely and critically ill patients with COVID-19: A Japanese multicenter inpatient database study"],"prefix":"10.1016","volume":"31","author":[{"given":"Tomoki","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideya","family":"Itagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0103-415X","authenticated-orcid":false,"given":"Shiro","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2024.09.020_bib1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12913-023-09362-2","article-title":"COVID-19 severity scale for claims data research","volume":"23","author":"Krause","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jiac.2024.09.020_bib2","article-title":"A study on the predictors of disease severity of COVID-19","volume":"26","author":"Li","year":"2020","journal-title":"Med Sci Mon Int Med J Exp Clin Res"},{"key":"10.1016\/j.jiac.2024.09.020_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2024.04.007","article-title":"Evaluating the association of body mass index with COVID-19 severity and mortality using Japanese administrative claims data","author":"Imoto","year":"2024","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2024.09.020_bib4","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s13054-021-03794-0","article-title":"The impact of COVID-19 critical illness on new disability, functional outcomes and return to work at 6 months: a prospective cohort study","volume":"25","author":"Hodgson","year":"2021","journal-title":"Crit Care"},{"key":"10.1016\/j.jiac.2024.09.020_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.12788\/jhm.3612","article-title":"Variation in COVID-19 mortality across 117 US hospitals in high- and low-burden settings","volume":"16","author":"Block","year":"2021","journal-title":"J Hosp Med"},{"key":"10.1016\/j.jiac.2024.09.020_bib6","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.15585\/mmwr.mm7137a4","article-title":"Mortality risk among patients hospitalized primarily for COVID-19 during the Omicron and Delta variant pandemic periods - United States, April 2020-June 2022","volume":"71","author":"Adjei","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jiac.2024.09.020_bib7","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1001\/jama.2023.5348","article-title":"Risk of death in patients hospitalized for COVID-19 vs seasonal influenza in fall-winter 2022-2023","volume":"329","author":"Xie","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2024.09.020_bib8","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1097\/CCM.0000000000004899","article-title":"Surviving sepsis campaign guidelines on the management of adults with Coronavirus disease 2019 (COVID-19) in the ICU: first update","volume":"49","author":"Alhazzani","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jiac.2024.09.020_bib9","article-title":"Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19","author":"Bhimraj","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.09.020_bib10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cmi.2021.11.007","article-title":"ESCMID COVID-19 living guidelines: drug treatment and clinical management","volume":"28","author":"Bartoletti","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2024.09.020_bib11","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jiac.2024.09.020_bib12","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","author":"Horby","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.jiac.2024.09.020_bib13","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(22)00088-1","article-title":"Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial","volume":"10","author":"Wolfe","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jiac.2024.09.020_bib14","article-title":"Use of baricitinib in combination with remdesivir and steroid in COVID-19 treatment: a multicenter retrospective study","volume":"13","author":"So","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jiac.2024.09.020_bib15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jmii.2021.05.009","article-title":"Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: a retrospective analysis","volume":"54","author":"P\u00e9rez-Alba","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jiac.2024.09.020_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.37737\/ace.1.3_76","article-title":"Real world data in Japan: chapter II the diagnosis procedure combination database","volume":"1","author":"Yasunaga","year":"2019","journal-title":"Ann Clin Epidemiol"},{"key":"10.1016\/j.jiac.2024.09.020_bib17","unstructured":"Ministry of Health, Labour and Welfare of Japan. Guideline for COVID-19 2024. https:\/\/www.mhlw.go.jp\/content\/001248424.pdf."},{"key":"10.1016\/j.jiac.2024.09.020_bib18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.resinv.2020.08.005","article-title":"Prediction model for prolonged length of stay in patients with community-acquired pneumonia based on Japanese administrative data","volume":"59","author":"Uematsu","year":"2021","journal-title":"Respir Investig"},{"key":"10.1016\/j.jiac.2024.09.020_bib19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jiac.2024.09.020_bib20","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.jiac.2024.09.020_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad571","article-title":"Effect of inhaled ciclesonide in non-critically ill hospitalized patients with Coronavirus disease 2019: a multicenter observational study in Japan","volume":"10","author":"Suzuki","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2024.09.020_bib22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2024.09.020_bib23","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","article-title":"Glucocorticoids-all-rounders tackling the versatile players of the immune system","volume":"10","author":"Strehl","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jiac.2024.09.020_bib24","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3389\/fimmu.2019.01545","article-title":"A general introduction to glucocorticoid biology","volume":"10","author":"Timmermans","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jiac.2024.09.020_bib25","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3389\/fimmu.2018.01736","article-title":"Immune effects of corticosteroids in sepsis","volume":"9","author":"Heming","year":"2018","journal-title":"Front Immunol"},{"year":"2018","series-title":"HIGHLIGHTS OF PRESCRIBING INFORMATION OLUMIANT (baricitinib)","key":"10.1016\/j.jiac.2024.09.020_bib26"},{"key":"10.1016\/j.jiac.2024.09.020_bib27","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/08971900221100205","article-title":"Bioavailability of orally administered drugs in critically ill patients","volume":"36","author":"Forsberg","year":"2023","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.jiac.2024.09.020_bib28","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40264-020-00958-9","article-title":"Thromboembolic safety reporting of tofacitinib and baricitinib: an analysis of the WHO VigiBase","volume":"43","author":"Vallejo-Yag\u00fce","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.jiac.2024.09.020_bib29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24002721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24002721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:47:25Z","timestamp":1738928845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24002721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1341321X24002721"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.09.020","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of baricitinib and corticosteroid compared to that of corticosteroid monotherapy in severely and critically ill patients with COVID-19: A Japanese multicenter inpatient database study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102531"}}